secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001437749-23-008313
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia reports FY2022 net loss $11.9M, cash runway into Q3 2023; clinical milestones ahead
--------------------------------------------------------------------------------

- Net loss $11.9M in 2022 vs $12.6M in 2021; revenue $1.4M up from $1.0M.
- Cash $7.4M at year-end provides runway into Q3 2023.
- CardiAMP Phase III heart failure trial enrolled 119 patients; DSMB cleared, adaptive SAP submitted.
- NK1R+ MSC allogeneic trial for HFrEF (BCDA-03) IND approved; first patient expected Q2 2023.
- Japan submission for CardiAMP approval planned for Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/0001437749-23-008313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/bcda20230328_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer